Sign up to save your podcasts
Or
Share Life Lessons from Lung Cancer survivor Matt Hiznay
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Life Lessons from Lung Cancer survivor Matt Hiznay
AN IMPACTFUL NEW CAMPAIGN IS KICKING OFF… PAIRING PATIENTS WITH SCIENTISTS RESPONSIBLE FOR CUTTING-EDGE ADVANCES IN MEDICINE. JOINING US IS ONE OF THE PATIENTS FEATURED IN THE CAMPAIGN, MATT HIZNAY (His-Nay), A 29-YEAR OLD LUNG CANCER SURVIVOR WHO WAS FIRST DIAGNOSED AT 24 YEARS OF AGE.
MATT: CAN YOU TELL US MORE ABOUT THIS NEW CAMPAIGN? YOU HAVE AN INTERESTING PERSONAL JOURNEY WITH CLINICAL TRIALS AND NOVEL TREATMENTS. TELL US A BIT ABOUT THAT.MATT: WHEN YOU FIRST BEGAN THE CLINICAL TRIALS AND THE NEW TREATMENT, WERE YOU OPTIMISTIC ABOUT YOUR CHANCES OF SURVIVAL DESPITE THE LONG ODDS?WHAT IS ONE THING AS A PATIENT AND A SURVIVOR THAT YOU WANT CANCER RESEARCHERS TO KNOW ABOUT YOUR STORY. AS A STUDENT STUDYING THESE ADVANCEMENTS NOW, WHAT EXCITES YOU MOST ABOUT WHAT IS ON THE HORIZON FOR CANCER TREATMENTS?DO YOU THINK WE WILL SEE A CURE FOR CANCER IN OUR LIFETIME?
Name: Matt Hiznay Age: 30Cleveland, Ohio...Matt Hiznay is a five-year survivor of metastatic lung cancer and a Ph.D. candidate studying cancer molecular genetics. Matt was a second-year medical student in 2011 when he was initially diagnosed with metastatic lung cancer, despite never having smoked in his life. His cancer developed rapidly, causing Matt to experience the complications a lung cancer patient normally experiences over several years within five days.
In a twist of fate, the U.S. Food and Drug Administration (FDA) approved a new drug, crizotinib (Xalkori, Pfizer), which happened to target his specific form of lung cancer, on the same day he received his diagnosis. He has now survived five years, a feat that only 1% have experienced.
View all episodes
By Rick TocquignyAN IMPACTFUL NEW CAMPAIGN IS KICKING OFF… PAIRING PATIENTS WITH SCIENTISTS RESPONSIBLE FOR CUTTING-EDGE ADVANCES IN MEDICINE. JOINING US IS ONE OF THE PATIENTS FEATURED IN THE CAMPAIGN, MATT HIZNAY (His-Nay), A 29-YEAR OLD LUNG CANCER SURVIVOR WHO WAS FIRST DIAGNOSED AT 24 YEARS OF AGE.
MATT: CAN YOU TELL US MORE ABOUT THIS NEW CAMPAIGN? YOU HAVE AN INTERESTING PERSONAL JOURNEY WITH CLINICAL TRIALS AND NOVEL TREATMENTS. TELL US A BIT ABOUT THAT.MATT: WHEN YOU FIRST BEGAN THE CLINICAL TRIALS AND THE NEW TREATMENT, WERE YOU OPTIMISTIC ABOUT YOUR CHANCES OF SURVIVAL DESPITE THE LONG ODDS?WHAT IS ONE THING AS A PATIENT AND A SURVIVOR THAT YOU WANT CANCER RESEARCHERS TO KNOW ABOUT YOUR STORY. AS A STUDENT STUDYING THESE ADVANCEMENTS NOW, WHAT EXCITES YOU MOST ABOUT WHAT IS ON THE HORIZON FOR CANCER TREATMENTS?DO YOU THINK WE WILL SEE A CURE FOR CANCER IN OUR LIFETIME?
Name: Matt Hiznay Age: 30Cleveland, Ohio...Matt Hiznay is a five-year survivor of metastatic lung cancer and a Ph.D. candidate studying cancer molecular genetics. Matt was a second-year medical student in 2011 when he was initially diagnosed with metastatic lung cancer, despite never having smoked in his life. His cancer developed rapidly, causing Matt to experience the complications a lung cancer patient normally experiences over several years within five days.
In a twist of fate, the U.S. Food and Drug Administration (FDA) approved a new drug, crizotinib (Xalkori, Pfizer), which happened to target his specific form of lung cancer, on the same day he received his diagnosis. He has now survived five years, a feat that only 1% have experienced.